Inclusion Criteria:~* Male or female; 50 - 95 years old with mild Alzheimer's disease determined after
neurological and neuropsychological evaluation following the National Institute on Aging - Alzheimer's disease
Association criteria that recently revisited the NINCDS-ADRDA criteria. For mild Alzheimer's disease, Clinical
Dementia Ratings Scale (CDR) should be 0.5 or 1 and Mini Mental State Examination (MMSS) between 19 and 27.~*
Must be on donepezil (AriceptÂ®) or rivastigmine (ExelonÂ®) or galantamine (RazadyneÂ®) at a consistent dose
for at least 2 months. Patients will be considered for inclusion if they were previously unable to tolerate
acetylcholinesterase inhibitors and as a result, are no longer on the medication for at least 2 months.~* Must
be fluent in English~* The subject will appoint or have previously appointed a health care proxy specifically
designated for research consent and that this be documented.~
